Arthneeti

Bal Pharma Share Price & Earnings Call Analysis

₹81.80+1.23% today
Market cap
₹130 Cr
P/E
18.09
ROE
7.79%
PEG
0.52
Price to sales
0.39
Debt to equity
1.94
52W high / low
₹114 / ₹60.4
Sales growth (5Y)
4.46%
EBITDA margin
10.11%
Net profit margin
2.01%
Promoter holding
50.87%
Sales (last year)
₹334 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Bal Pharma rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Bal Pharma.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Bal Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Bal Pharma

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +82.4570.3992.5481.6694.6374.3673.6973.1581.8865.8774.0287.6984.08
Expenses +74.2963.9584.8473.8785.0367.8966.0065.4074.2459.8168.2978.1573.50
Operating Profit8.166.447.707.799.606.477.697.757.646.065.739.5410.58
OPM %9.90%9.15%8.32%9.54%10.14%8.70%10.44%10.59%9.33%9.20%7.74%10.88%12.58%
Other Income +0.190.160.140.102.450.82-0.200.511.080.721.120.33-0.24
Interest3.853.643.823.664.144.243.655.013.954.053.864.854.06
Depreciation2.092.532.422.962.162.432.482.692.182.522.273.233.06
Profit before tax2.410.431.601.275.750.621.360.562.590.210.721.793.22
Tax %32.78%79.07%39.38%33.07%3.65%58.06%23.53%7.14%-108.88%0.00%0.00%0.00%-12.11%
Net Profit +1.620.090.970.855.530.261.040.525.410.210.721.793.60
EPS in Rs1.020.050.610.563.460.160.650.303.410.130.451.122.25

Financials of Bal Pharma

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +187198229211225171251281304339303312
Expenses +170183214194207166226257279308273280
Operating Profit17151517185252425313032
OPM %9%7%6%8%8%3%10%9%8%9%10%10%
Other Income +113212151322
Interest76891313121112151717
Depreciation7767681099101011
Profit before tax5333-0-14495956
Tax %25%90%114%87%-1,175%-5%-15%38%45%18%-41%-7%
Net Profit +41-002-13563776
EPS in Rs2.821.101.241.962.67-8.623.203.781.644.684.533.94
Dividend Payout %35%91%81%51%37%0%31%26%61%26%26%0%

Financials of Bal Pharma

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital131314141414151516161616
Reserves424248515238394448566266
Borrowings +498993110124118110104131140150160
Other Liabilities +5967788671687698116108108134
Total Liabilities164211233260261238240261311320336376
Fixed Assets +525660717071696776808794
CWIP142043020037
Investments000000000722
Other Assets +111151172188187164172192235233244272
Total Assets164211233260261238240261311320336376

Financials of Bal Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +15-19618232227-22320
Cash from Investing Activity +-5-14-8-4-8-5-6-9-22-19-15
Cash from Financing Activity +-732-640-20-17-1724-1-8
Net Cash Flow2-1-81-0-20003-2
Free Cash Flow9-34-2-3-1181918-16122
CFO/OP93%-125%52%11%57%465%91%117%-4%88%75%

Financials of Bal Pharma

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days88105991111051069898113107111110
Inventory Days132145172240217292146162207167238269
Days Payable142163171182147167114143167147189206
Cash Conversion Cycle7887100168175231130117153127161173
Working Capital Days1450264525-111118131267
ROCE %11%7%8%8%7%-0%10%12%10%12%10%10%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals